PD-L1 IHC 22C3 pharmDx and Non-small Cell Lung Cancer (NSCLC): One Assay, Two Platforms

The Precision Pathology Insights webinar series offers expert insight into consistently and confidently determining Combined Positive Score (CPS) across a range of tumor types, helping sharpen your command of PD-L1. This webinar is presented by Grant Toland, R&D Scientist in Agilent Technologies.​ Recorded on 8 December 2020.​

Expert insights into CPS from R&D Scientist in Agilent Technologies, Grant Toland:  ​

• Identification of parameters affecting staining performance​
• Precision analysis of PD-L1 IHC 22C3 pharmDx​
• Performance evaluation between the Dako Omnis and Autostainer platforms in non-small cell lung cancer (NSCLC)

This website discusses general principles for CDx scoring and is intended for educational purposes only. Not all cancer indications mentioned are approved worldwide. Please consult local Instructions for Use for more information.D0113746_1.00